Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
|
Outline of Final Research Achievements |
Aim of this study is to find a clinical biomarker for amrubicin treatment and its mechanism. We found that polymorphisms of ABCB1 have relationship with amrubicin-induced neutropenia. Also, we had a result that area under the plasma concentration versus time curve (AUC) values of amrubicinol have a significant relation with grade of neutropenia during amrubicin treatment. However, we could not reach to identify the factor which regulates AUC value of amrubicinol. We now focus on organic cation transporter (OCT) and have continued to investigate factors which regulate pharmacological function of amrubicin.
|